A New Insight into the Impact of Copy Number Variations on Cell Cycle Deregulation of Luminal-type Breast Cancer

Overview

Journal Oncol Rev

Specialty Oncology

Date 2025 Feb 28

PMID 40017494

Authors

Amir Mahdi Khamaneh

Davoud Jafari-Gharabaghlou

Khalil Ansarin

Pouya Pazooki

Zahra Akbarpour

Behrooz Naghili

Nosratollah Zarghami

Affiliations

Soon will be listed here.

Abstract

Breast cancer is the most prevalent neoplasm in women. ER (Luminal subtype), representing over 70% of breast tumors, is a genetically diverse group. Structural and Numerical-Chromosomal instability initiates tumor development and is recognized as the primary driver of genetic alteration in luminal breast tumors. Genomic instability refers to the increased tendency of cancer cells to accumulate genomic alterations during cell proliferation. The cell cycle check-point response to constant and stable genomic alterations in tumor cells drives this process. The impact of CNV patterns and aneuploidies in cell cycle and proliferation perturbation has recently been highlighted by scientists in Luminal breast tumors. The impact of chromosomal instability on cancer therapy and prognosis is not a new concept. Still, the degree of emerging genomic instability leads to prognosis alteration following cell cycle deregulation by chromosomal instability could be predicted by CNVs-based reclassification of breast tumors. In this review, we try to explain the effect of CIN in the cell cycle that ended with genomic instability and altered prognosis and the impact of CIN in decision-making for a therapy strategy for patients with luminal breast cancer.

References

Serra F, Lapidari P, Quaquarini E, Tagliaferri B, Sottotetti F, Palumbo R . Palbociclib in metastatic breast cancer: current evidence and real-life data. Drugs Context. 2019; 8:212579. PMC: 6668507. DOI: 10.7573/dic.212579. View

OConnor T, Schultz E, Wang J, OConnor T, Levine E, Knudsen E . Real-World Experience among Elderly Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitor-Based Therapy. Cancers (Basel). 2024; 16(9). PMC: 11083425. DOI: 10.3390/cancers16091749. View

Lategan K, Walters C, Pool E . The effects of silver nanoparticles on RAW 264.7. Macrophages and human whole blood cell cultures. Front Biosci (Landmark Ed). 2018; 24(2):347-365. DOI: 10.2741/4722. View

Mekonnen N, Yang H, Rajasekaran N, Song K, Choi Y, Shin Y . Indirect targeting of MYC and direct targeting in combination with chemotherapies are more effective than direct mono-targeting in triple negative breast cancer. Transl Oncol. 2024; 51:102204. PMC: 11652953. DOI: 10.1016/j.tranon.2024.102204. View

Lee K, Kim H, Jang M, Lee S, Ahn S, Park S . Centromere 17 copy number gain reflects chromosomal instability in breast cancer. Sci Rep. 2019; 9(1):17968. PMC: 6884473. DOI: 10.1038/s41598-019-54471-w. View

Pfister K, Pipka J, Chiang C, Liu Y, Clark R, Keller R . Identification of Drivers of Aneuploidy in Breast Tumors. Cell Rep. 2018; 23(9):2758-2769. PMC: 5997284. DOI: 10.1016/j.celrep.2018.04.102. View

Cavalli F, Remke M, Rampasek L, Peacock J, Shih D, Luu B . Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell. 2017; 31(6):737-754.e6. PMC: 6163053. DOI: 10.1016/j.ccell.2017.05.005. View

Martinez-Alonso D, Malumbres M . Mammalian cell cycle cyclins. Semin Cell Dev Biol. 2020; 107:28-35. DOI: 10.1016/j.semcdb.2020.03.009. View

Rueda O, Sammut S, Seoane J, Chin S, Caswell-Jin J, Callari M . Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. Nature. 2019; 567(7748):399-404. PMC: 6647838. DOI: 10.1038/s41586-019-1007-8. View

10.

Williams R, Zhang X . Roles of ATM and ATR in DNA double strand breaks and replication stress. Prog Biophys Mol Biol. 2020; 161:27-38. DOI: 10.1016/j.pbiomolbio.2020.11.005. View

11.

Hartwell L, Kastan M . Cell cycle control and cancer. Science. 1994; 266(5192):1821-8. DOI: 10.1126/science.7997877. View

12.

Ozeri-Galai E, Schwartz M, Rahat A, Kerem B . Interplay between ATM and ATR in the regulation of common fragile site stability. Oncogene. 2007; 27(15):2109-17. DOI: 10.1038/sj.onc.1210849. View

13.

Wilhelm T, Said M, Naim V . DNA Replication Stress and Chromosomal Instability: Dangerous Liaisons. Genes (Basel). 2020; 11(6). PMC: 7348713. DOI: 10.3390/genes11060642. View

14.

Wilson T, Arlt M, Park S, Rajendran S, Paulsen M, Ljungman M . Large transcription units unify copy number variants and common fragile sites arising under replication stress. Genome Res. 2014; 25(2):189-200. PMC: 4315293. DOI: 10.1101/gr.177121.114. View

15.

Zhou C, Zhang W, Chen W, Yin Y, Atyah M, Liu S . Integrated Analysis of Copy Number Variations and Gene Expression Profiling in Hepatocellular carcinoma. Sci Rep. 2017; 7(1):10570. PMC: 5585301. DOI: 10.1038/s41598-017-11029-y. View

16.

Heng H, Stevens J, Liu G, Bremer S, Ye K, Reddy P . Stochastic cancer progression driven by non-clonal chromosome aberrations. J Cell Physiol. 2006; 208(2):461-72. DOI: 10.1002/jcp.20685. View

17.

Rakha E, Armour J, Pinder S, Paish C, Ellis I . High-resolution analysis of 16q22.1 in breast carcinoma using DNA amplifiable probes (multiplex amplifiable probe hybridization technique) and immunohistochemistry. Int J Cancer. 2004; 114(5):720-9. DOI: 10.1002/ijc.20738. View

18.

Imani M, Mohajeri N, Rastegar M, Zarghami N . Synthesis and characterization of N-rich fluorescent bio-dots as a reporter in the design of dual-labeled FRET probe for TaqMan PCR: A feasibility study. Biotechnol Appl Biochem. 2022; 70(2):645-658. DOI: 10.1002/bab.2387. View

19.

Sahabi S, Jafari-Gharabaghlou D, Zarghami N . A new insight into cell biological and biochemical changes through aging. Acta Histochem. 2022; 124(1):151841. DOI: 10.1016/j.acthis.2021.151841. View

20.

Krig S, Miller J, Frietze S, Beckett L, Neve R, Farnham P . ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells. Oncogene. 2010; 29(40):5500-10. PMC: 4256946. DOI: 10.1038/onc.2010.289. View